Tags

Type your tag names separated by a space and hit enter

Risk factors for statin-associated rhabdomyolysis.
Pharmacoepidemiol Drug Saf 2007; 16(3):352-8PD

Abstract

PURPOSE

To identify and characterize risk factors for rhabdomyolysis in patients prescribed statin monotherapy or statin plus fibrate therapy.

METHODS

A nested case-control study was conducted within a cohort of 252,460 new users of lipid-lowering medications across 11 geographically dispersed U.S. health plans. Twenty-one cases of rhabdomyolysis confirmed by medical record review were compared to 200 individually matched controls without rhabdomyolysis. A conditional logistic regression model was applied to evaluate the effects of age, gender, comorbidities, concurrent medication use, dosage, and duration of statin use on the development of rhabdomyolysis.

RESULTS

Statin users 65 years of age and older have four times the risk of hospitalization for rhabdomyolysis than those under age 65 (odds ratio (OR) = 4.36, 95% confidence interval (CI): 1.5,14.1). We also observed a joint effect of high statin dosage and renal disease (p = 0.022). When these two variables were added to the model with age, we obtained an OR of 5.73 for dosage (95%CI: 0.63, 52.6) and 6.26 for renal disease (95%CI: 0.46, 63.38). Although not statistically significant, we did observe a greater than twofold increase in risk for rhabdomyolysis among females (OR = 2.53, 95%CI: 0.91, 7.32).

CONCLUSIONS

Findings of this study indicate that older age is a risk factor for rhabdomyolysis among statin users. Although the evidence is not as strong, high statin dosage, renal disease, and female gender may be additional risk factors. Patients at higher risk of developing rhabdomyolysis should be closely monitored for signs and symptoms of the disease.

Authors+Show Affiliations

Center for Health Care Policy and Evaluation, Eden Prairie, MN 55344, USA. stephanie_d_schech@uhc.comNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, U.S. Gov't, P.H.S.

Language

eng

PubMed ID

16892458

Citation

Schech, Stephanie, et al. "Risk Factors for Statin-associated Rhabdomyolysis." Pharmacoepidemiology and Drug Safety, vol. 16, no. 3, 2007, pp. 352-8.
Schech S, Graham D, Staffa J, et al. Risk factors for statin-associated rhabdomyolysis. Pharmacoepidemiol Drug Saf. 2007;16(3):352-8.
Schech, S., Graham, D., Staffa, J., Andrade, S. E., La Grenade, L., Burgess, M., ... Shatin, D. (2007). Risk factors for statin-associated rhabdomyolysis. Pharmacoepidemiology and Drug Safety, 16(3), pp. 352-8.
Schech S, et al. Risk Factors for Statin-associated Rhabdomyolysis. Pharmacoepidemiol Drug Saf. 2007;16(3):352-8. PubMed PMID: 16892458.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Risk factors for statin-associated rhabdomyolysis. AU - Schech,Stephanie, AU - Graham,David, AU - Staffa,Judy, AU - Andrade,Susan E, AU - La Grenade,Lois, AU - Burgess,Margaret, AU - Blough,David, AU - Stergachis,Andy, AU - Chan,K Arnold, AU - Platt,Richard, AU - Shatin,Deborah, PY - 2006/8/8/pubmed PY - 2007/4/18/medline PY - 2006/8/8/entrez SP - 352 EP - 8 JF - Pharmacoepidemiology and drug safety JO - Pharmacoepidemiol Drug Saf VL - 16 IS - 3 N2 - PURPOSE: To identify and characterize risk factors for rhabdomyolysis in patients prescribed statin monotherapy or statin plus fibrate therapy. METHODS: A nested case-control study was conducted within a cohort of 252,460 new users of lipid-lowering medications across 11 geographically dispersed U.S. health plans. Twenty-one cases of rhabdomyolysis confirmed by medical record review were compared to 200 individually matched controls without rhabdomyolysis. A conditional logistic regression model was applied to evaluate the effects of age, gender, comorbidities, concurrent medication use, dosage, and duration of statin use on the development of rhabdomyolysis. RESULTS: Statin users 65 years of age and older have four times the risk of hospitalization for rhabdomyolysis than those under age 65 (odds ratio (OR) = 4.36, 95% confidence interval (CI): 1.5,14.1). We also observed a joint effect of high statin dosage and renal disease (p = 0.022). When these two variables were added to the model with age, we obtained an OR of 5.73 for dosage (95%CI: 0.63, 52.6) and 6.26 for renal disease (95%CI: 0.46, 63.38). Although not statistically significant, we did observe a greater than twofold increase in risk for rhabdomyolysis among females (OR = 2.53, 95%CI: 0.91, 7.32). CONCLUSIONS: Findings of this study indicate that older age is a risk factor for rhabdomyolysis among statin users. Although the evidence is not as strong, high statin dosage, renal disease, and female gender may be additional risk factors. Patients at higher risk of developing rhabdomyolysis should be closely monitored for signs and symptoms of the disease. SN - 1053-8569 UR - https://www.unboundmedicine.com/medline/citation/16892458/Risk_factors_for_statin_associated_rhabdomyolysis_ L2 - https://doi.org/10.1002/pds.1287 DB - PRIME DP - Unbound Medicine ER -